Sign In
Buy NTRA
$234.76
+5.96 (+2.60%)
At Close: Jun 23, 2026
Natera, Inc. (NTRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
10:46pm, Tuesday, 13'th Jan 2026
Natera, Inc. (NTRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NTRA & NVDA Partner to Improve AI Models for Precision Medicine
11:45am, Tuesday, 13'th Jan 2026
Natera teams up with NVIDIA to train multimodal AI models, aiming to improve precision care through faster, scalable analysis of complex medical data.
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
08:00am, Tuesday, 13'th Jan 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced an advancement in molecular residual disease (MRD)
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA
10:00am, Monday, 12'th Jan 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a new collaboration with NVIDIA to accelerate the developme
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth
10:48pm, Sunday, 11'th Jan 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today released preliminary unaudited results for the fourth quarter and full year
Farther Finance Advisors LLC Lowers Position in Natera, Inc. $NTRA
04:02am, Thursday, 08'th Jan 2026
Farther Finance Advisors LLC decreased its position in shares of Natera, Inc. (NASDAQ: NTRA) by 77.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange
Pre-Market Stock Futures: The futures are trading flat on Wednesday after a second strong day for Wall Street, as the Dow Jones Industrial Average hit another record high, closing over $49,000 for the
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
08:00am, Wednesday, 07'th Jan 2026
ALAMEDA, Calif. & AUSTIN, Texas--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Natera (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced their collaboration
Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI
07:25pm, Monday, 05'th Jan 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that new data from the ALTAIR trial will be presented at the 2026
Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology
07:00am, Monday, 05'th Jan 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of Natera's expanded 21-gene Fetal Focus single gene no
Medical Stock Hovers Near Buy Point After 46% Gain
01:49pm, Tuesday, 30'th Dec 2025
Natera stock is near its all-time high after gaining 46% year to date.
Cwm LLC Increases Stake in Natera, Inc. $NTRA
04:07am, Monday, 29'th Dec 2025
Cwm LLC raised its stake in Natera, Inc. (NASDAQ: NTRA) by 72.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 70,925 s
Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference
08:00am, Monday, 22'nd Dec 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will participate in the 44th Annual J.P. Morgan Healthcare
Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
08:00am, Thursday, 18'th Dec 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of findings from the randomized, phase III CALGB (
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Quantum Leap Healthcare Collaborative, today announced the publicati
